10,764 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Bought by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd purchased a new stake in Tango Therapeutics, Inc. (NASDAQ:TNGX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 10,764 shares of the company’s stock, valued at approximately $33,000.

A number of other institutional investors also recently modified their holdings of the company. Teacher Retirement System of Texas grew its holdings in shares of Tango Therapeutics by 35.8% during the fourth quarter. Teacher Retirement System of Texas now owns 14,544 shares of the company’s stock worth $45,000 after buying an additional 3,831 shares in the last quarter. Wells Fargo & Company MN grew its stake in shares of Tango Therapeutics by 51.7% during the 4th quarter. Wells Fargo & Company MN now owns 22,292 shares of the company’s stock worth $69,000 after acquiring an additional 7,599 shares in the last quarter. Swiss National Bank grew its stake in shares of Tango Therapeutics by 13.1% during the 4th quarter. Swiss National Bank now owns 94,900 shares of the company’s stock worth $293,000 after acquiring an additional 11,000 shares in the last quarter. American Century Companies Inc. raised its holdings in shares of Tango Therapeutics by 12.4% in the fourth quarter. American Century Companies Inc. now owns 110,448 shares of the company’s stock valued at $341,000 after purchasing an additional 12,162 shares during the last quarter. Finally, Sequoia Financial Advisors LLC bought a new stake in shares of Tango Therapeutics in the fourth quarter worth $45,000. 78.99% of the stock is currently owned by institutional investors.

Tango Therapeutics Trading Up 9.3 %

Tango Therapeutics stock opened at $1.41 on Friday. Tango Therapeutics, Inc. has a 1-year low of $1.11 and a 1-year high of $12.02. The company has a fifty day simple moving average of $1.96 and a 200 day simple moving average of $3.47. The company has a market cap of $152.43 million, a P/E ratio of -1.19 and a beta of 1.03.

Tango Therapeutics (NASDAQ:TNGX) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Tango Therapeutics had a negative net margin of 284.42% and a negative return on equity of 49.64%. The company had revenue of $4.12 million during the quarter, compared to the consensus estimate of $7.84 million. On average, equities research analysts forecast that Tango Therapeutics, Inc. will post -1.19 EPS for the current year.

Insider Buying and Selling at Tango Therapeutics

In other news, CEO Barbara Weber sold 9,778 shares of the stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $2.99, for a total value of $29,236.22. Following the completion of the sale, the chief executive officer now owns 1,631,264 shares of the company’s stock, valued at approximately $4,877,479.36. This represents a 0.60 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 24,268 shares of company stock worth $72,561 over the last ninety days. 6.30% of the stock is currently owned by corporate insiders.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.